1Jung BF, Johnson RW, Griffin DR et al. Risk factors for postherpetic neuralgia in patients with herpes zoster [ J ]. Neurology ,2004,62 ( 9 ) : 1 545-1 551.
7Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008,197(Suppl 2) :S207-S215.
8Decroix J, Partsch H, Gonzalez R, et al. Factors influencing pain outcome in herpes zoster: an observational study with valaciclovir[J]. J.Eur.Acad.Dermatol Venereol, 2000, 14: 23-33.
9Semel D, Murphy TK, Zlateva G, et al. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies[J].BMC Fam Pract,2010, 1 ( 11 ) : 85.
10Harpaz R, Nagel MA, Schmader K, et al. Roundtable on Postherpetic euralgia-What, Why, How Long, and What's Next[J]. Popul Health Manag,2012,15 ( 6 ) : 385-390.
